Thanks for posting that. Pretty interesting! I watched the one about 'generic process' and he mentioned that $5B is the average cost of getting a molecule to market. Sounds pretty scary, but he also says there is a lot of variation in that and I'm assuming this means every cent spent on research from the beginning up to big trials. And presumably orphan drugs would potentially be much less, at least in my thinking.

The nice thing about MANF is that so many people, much of them working with public funding (ie. universities) are doing the fundamental research. It's still a little confusing to me exactly what we have patents over and can therefore license, but I imagine this will clarify as interest and research evolves and becomes more specific as indications clarify. i also think this IP area is grey in general.